130 related articles for article (PubMed ID: 9059560)
1. Elevated fibrinogen levels decrease following treatment of acromegaly.
Landin-Wilhelmsen K; Tengborn L; Wilhelmsen L; Bengtsson BA
Clin Endocrinol (Oxf); 1997 Jan; 46(1):69-74. PubMed ID: 9059560
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure.
Landin K; Petruson B; Jakobsson KE; Bengtsson BA
Acta Endocrinol (Copenh); 1993 May; 128(5):418-22. PubMed ID: 8317188
[TBL] [Abstract][Full Text] [Related]
3. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
4. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
6. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral glucose on acylated and total ghrelin secretion in acromegalic patients.
Isidro ML; Nemina R; Garcia-Buela J; Sangiao-Alvarellos S; Cordido F
Neuro Endocrinol Lett; 2007 Oct; 28(5):596-603. PubMed ID: 17984943
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin.
Landin-Wilhelmsen K; Wilhelmsen L; Lappas G; Rosén T; Lindstedt G; Lundberg PA; Bengtsson BA
Clin Endocrinol (Oxf); 1994 Sep; 41(3):351-7. PubMed ID: 7955442
[TBL] [Abstract][Full Text] [Related]
9. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.
Delaroudis SP; Efstathiadou ZA; Koukoulis GN; Kita MD; Farmakiotis D; Dara OG; Goulis DG; Makedou A; Makris P; Slavakis A; Avramides AI
Clin Endocrinol (Oxf); 2008 Aug; 69(2):279-84. PubMed ID: 18194486
[TBL] [Abstract][Full Text] [Related]
11. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of insulin-like growth factor binding protein-3 levels to determine acromegaly activity and effectiveness of transsphenoidal pituitary surgery.
Ochoa R; Mercado M; Chacón X; Fonseca E; Hernández M; Zárate A
Arch Med Res; 1999; 30(4):303-6. PubMed ID: 10573632
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
15. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.
Reyes-Vidal C; Fernandez JC; Bruce JN; Crisman C; Conwell IM; Kostadinov J; Geer EB; Post KD; Freda PU
J Clin Endocrinol Metab; 2014 Nov; 99(11):4124-32. PubMed ID: 25137427
[TBL] [Abstract][Full Text] [Related]
18. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly.
Vilar L; Naves LA; Costa SS; Abdalla LF; Coelho CE; Casulari LA
Endocr Pract; 2007; 13(4):363-72. PubMed ID: 17669712
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
20. Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects.
Li Voon Chong JS; Benbow S; Foy P; Wallymahmed ME; Wile D; MacFarlane IA
Clin Endocrinol (Oxf); 2000 Nov; 53(5):551-9. PubMed ID: 11106915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
